ulrich medical receives extension of approval in the area of contrast-enhanced mammography

The syringeless contrast media injectors Max 2M and Max 3 from ulrich medical can now also be used in contrast-enhanced, digital mammography.

The two devices were officially approved for the new area of application on the occasion of international breast cancer month in October. Now users from the field of contrast-enhanced breast cancer diagnostics can also benefit from the advantages of the injectors produced by the medical technology manufacturer based in Ulm, Germany. These include proven ease of operation, a high level of hygienic safety for both patients and users and flexible positioning in the examination rooms, which are usually small.

With approx. 70,000 new cases each year, breast cancer is the most frequent cancer disease amongst women in Germany. World Breast Cancer Day is an annual event that highlights how important it is to detect this disease early. Mammography is currently considered the most effective method for the early detection of breast cancer in women between the ages of 50 and 69[1]. However, in some cases, conventional digital mammography is not sufficient to make malignant tumors visible. The contrast of the tumor to the surrounding tissue may be so low that it is concealed by normal gland tissue. Contrast-enhanced mammograms are now being carried out more and more in order to increase these contrasts. With this, ulrich medical recognized the opportunity to use its contrast media injectors to support in the diagnostics of breast cancer and therefore increase the chances of early detection and recovery.

As with CT and MRI examinations, the use of a contrast media injector can ensure a continuous flow of contrast media. Furthermore, the automated injection of contrast media ensures fast and efficient workflow. Unlike manual injections, the bolus is administered accurately, which then increases the quality of the imaging.

Max 2M and Max 3 enhance digital breast cancer diagnostics

Chief Executive Officer, Klaus Kiesel, is delighted that ulrich medical is making such a purposeful contribution to contrast-media-enhanced mammography diagnostics with the extension of approval for Max 2M and Max 3: “Now that we have this approval, we’ve been able to successfully tap into this important market segment because once again we’ve successfully fulfilled our role as a solution provider for our customers. You just have to understand exactly where the challenges are in the everyday lives of our customers and users, then targeted solutions can be developed”.

In this way users in contrast-enhanced mammography can now also benefit from the simple and user-friendly handling of the injectors from ulrich medical. Because the special multi-use concept for the disposable material of the contrast media injectors from ulrich medical simplifies the workflow. Once prepared, they are ready-to-use at any time and can be used for the entire day. For the examination itself, it takes the user only a few maneuvers and the injector automatically does the rest. For patient changeover, only the patient tubing must be changed and this only takes a few seconds. It’s a successful concept that helps users worldwide to cope with the constantly increasing patient turnover.

Thanks to their small dimensions, Max 2M and Max 3 are ideal for use in confined spaces. As they are battery operated, they’re extremely maneuverable, allowing them to be positioned anywhere in the examination room. The application of the contrast media itself can then be started quickly and easily directly from the injector control unit.

[1] Federal Office for Radiation Protection: “The Mammography Screening Program in Germany” (https://www.bfs.de/DE/themen/ion/anwendung-medizin/diagnostik/roentgen/mammographie.html)